Biomarkers for Diagnosis and Prognosis of MS

It is an exciting period for the clinical management of multiple sclerosis (MS), with an expanding treatment landscape and recent approval of new disease-modifying therapies (DMTs) for both relapsing and progressive MS. The Consortium of Multiple Sclerosis Centers (CMSC) 2019 Annual Meeting, the largest MS meeting in North America, features the latest information on cutting-edge research findings, clinical advances in the diagnosis and management of MS, and emerging care issues, as well as new MS practice trends, innovative care practices, and health policy issues affecting access to care.

However, while annual meetings are avenues for the release of emerging data, community clinicians are often unable to attend due to busy schedules and patient loads. As it is critical that neurologists involved in the care of patients with MS learn how to evaluate and apply the latest advances, CME Outfitters presents a 3-part series of podcasts that will examine and translate the emerging data to practice. Part 1 will identify and present the most important information on diagnostic modalities and biomarkers as tools to guide clinical decision-making.